Jan de Backer – CEO, Fluidda
Fluidda is the world leader in the field of functional respiratory imaging which combines HRCT scans and computational fluid dynamics technology. CEO Jan de Backer outlines the major developments of…
Address: Groeningenlei 132
2550 Kontich
Groeningenlei 132, 2550 Kontich,Belgium
Tel: +32 3 450 87 20
FluidDA acts as a CRO to support the implementation of the FluidDA imaging biomarkers into clinical trials and clinical practice. To offer a high quality service, FluidDA employs experts in all required fields from medical doctors to biomedical scientists and engineers. A complete package is offered to manage a study from design to (scientific) reporting.
FluidDA has experience in pulmonology, respiratory drug delivery, sleep medicine, maxillofacial surgery and cardiovascular. The company collects stores, manages and analyzes data coming from a variety of imaging modalities such as CT, MRI, Cone Beam CT, SPECT and ultrasound. From clinical studies, FluidDA has gained extensive experience in scanning protocols to achieve proper image quality. FluidDA can write or assist in writing protocols for clinical imaging studies according to GCP guidelines as well as analyzing and writing of study results in international peer reviewed journals.
Fluidda is the world leader in the field of functional respiratory imaging which combines HRCT scans and computational fluid dynamics technology. CEO Jan de Backer outlines the major developments of…
Dr De Backer looking into your background, we see that you have a background in aerospace engineering and applied biomedical computational fluid dynamics that is riddled with awards for your…
Vincent Stephenne, managing director of Belgian CDMO BePharBel Manufacturing, highlights the company’s innovative approach to developing new galenic forms for existing molecules, its growth trajectory thus far, and his future…
Christophe Van Damme, vice president and general manager of Perrigo Belgium and Luxembourg, shines a light on the transformation for Perrigo since its acquisition of Omega Pharma in 2015. Van…
Veronique Walsh, general manager of Bristol Myers Squibb for Belgium, the Netherlands, and Luxembourg (Benelux), recently spoke to PharmaBoardroom about her diverse career path, transitioning from medical doctor to pharmaceutical…
In an exclusive interview, GSK’s Senior VP for Vaccines R&D Dr Emmanuel Hanon discusses how the sharing of GSK’s adjuvant technology with a wealth of scientific institutions and companies globally…
Veronique Walsh, General Manager of Bristol Myers Squibb (BMS) – Benelux, explains her ambition to build a new company culture following the acquisition of Celgene. Walsh also lays bare the…
Stakeholders from the Belgian parallel trade industry outline how their activities are helping to solve medicine shortages in Europe and ensure patients have access to the medicines they need. They…
Geert Van Hoof, founding general manager of Chiesi Belgium, shares the exciting milestones of the company’s first decade in Belgium, including their stunning year-on-year double-digit growth, their market leadership in…
Tanguy Schmitz, president of the Belgian Association of Parallel Importers & Exporters (BAPIE) outlines some of the recent work that the parallel distribution industry to ensure the supply of medicines…
Four Belgium country managers for some of the world’s largest pharma companies give their words of wisdom for women starting out in the industry. “Focus on your strengths” Sonja…
Filip Van de Vliet and Gérard Lefèbvre of Alter Pharma Group discuss the value that parallel importing is bringing to Belgian patients and the evolving relationship between parallel importers and…
Marijke Eyssen of the Belgian Health Care Knowledge Centre (KCE) introduces the institution’s mission, core values, how it chooses areas of research, and the crucial work the KCE does in…
Janssen in Belgium was founded in 1953 by Dr Paul Janssen, with only one thing in mind: saving people’s lives through the development of better medicines. In 1961, the company…
See our Cookie Privacy Policy Here
